Showing results (201-210 of 824) with videos related to

Sort By:
Pageof 83
Cancer Research|December 17, 2005
Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implicationsYu-Tzu Tai, Xian-Feng Li, Laurence Catley, et al.
Open Journal of Hematology|June 14, 2013
Cell Trafficking in Multiple MyelomaGiada Bianchi, Shaji Kumar, Irene M Ghobrial, et al.
Current Oncology (Toronto, Ont.)|November 24, 2022
Treating Multiple Myeloma in the Context of the Bone Marrow MicroenvironmentMatthew Ho, Alexander Xiao, Dongni Yi, et al.
Cancer Research|August 17, 2005
FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistanceHiroshi Yasui, Teru Hideshima, Noopur Raje, et al.
Hematology. American Society of Hematology. Education Program|November 21, 2007
The treatment of relapsed and refractory multiple myelomaPaul Richardson, Constantine Mitsiades, Robert Schlossman, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 30, 2003
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implicationsConstantine S Mitsiades, Nicholas S Mitsiades, Ciaran J McMullan, et al.
Blood|April 2, 2005
SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myelomaHiroshi Yasui, Teru Hideshima, Makoto Hamasaki, et al.
Molecular Cancer Therapeutics|January 14, 2009
Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivoRenate Burger, Steven Le Gouill, Yu-Tzu Tai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2011
Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomideLoredana Santo, Teru Hideshima, Diana Cirstea, et al.
Blood|September 8, 2012
Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibitionMichele Cea, Antonia Cagnetta, Mariateresa Fulciniti, et al.
Pageof 83